1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Legal

Two Collagen Skin-Care False Advertising Suits In Same US District, Two Different Outcomes

 
• By Ryan Nelson

L’Oreal USA settled a putative class action in April that challenged Collagen Moisture Filler claims on L’Oreal skin-care product labels after New York’s Southern District denied its motion to dismiss. Algenist LLC on the other hand, prevailed in November 2022 in the same district in litigation concerning the truthfulness of “Advanced Anti-Aging” claims on Algenist Genius Collagen products.

• Source: Shutterstock

L’Oreal USA, Inc. and Algenist, LLC both market skin-care products with Collagen in their names and front-label anti-aging claims, and both were sued in the US District Court for the Southern District of New York by consumer plaintiffs alleging false advertising.

L’Oreal Collagen Moisture Filler Day/Night Cream and L’Oreal Fragrance-Free Collagen Moisture Filler Daily Moisturizer were labeled with claims such as “Restore skin’s cushion and smooth wrinkles” and “Visibly smooth wrinkles,” while Algenist Genius Collagen Calming Relief, Algenist Genius Liquid

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal

Supreme Court 1935 Ruling Limiting Executive Authority On Appointments ‘Unravels’ Today – DoJ

 
• By Malcolm Spicer

In complaint and response to motion to dismiss, Rebecca Kelly Slaughter’s and Alvaro Bedoya’s attorneys elaborate on Supreme Court ‘s 1935 decision, Humphrey’s Executor v. US. Administration attorneys, though, contend the ruling isn’t relevant to the current FTC.

Estee Lauder Faces Securities Fraud Suit After District Court Denies Motion To Dismiss

 
• By Eileen Francis

A federal judge in the Southern District of New York denied Estee Lauder’s motion to dismiss a securities fraud lawsuit filed by shareholders who said the company concealed its reliance on a gray market retail revenue stream, which ultimately caused sales and the stock price to plunge.

Uncertainty Abounds With SEC Climate Reporting Rule Tied Up In Courts

 
• By Lauren Nardella

Despite questions surrounding the SEC rule, including disputes being litigated in the US Eighth Circuit, companies must prepare to meet the new climate disclosure requirements in addition to related mandates in California and abroad. Experts emphasize opportunities beyond compliance.

In Emergency Rule, California Bans All THCs In Hemp Products: Industry Asks, Where’s The Fire?

 
• By Malcolm Spicer

California authorities say predominance of retailers licensed to sell hemp are compliant with ban published effective on 3 October through emergency regulation. But hemp industry’s contesting the regulation in state court, arguing state authorities inappropriately used emergency action to change state law on hemp products legislature passed in 2021.

More from Policy & Regulation

US Fragrance Firms Should Identify Domestic, Non-Tariff Sources Now – Fragrance House CEO

Firms in the US facing tariff costs should identify US-based, non-tariff sources and lobby local government officials and DC when foreign-sourced ingredients cannot be substituted in the US.

Cosmetics Consortium Shares Studies With FDA To Build Confidence In Animal Testing Alternatives

 
• By Lauren Nardella

By guiding regulators through case studies and mock dossier examples of how to utilize new approach methodologies, the International Collaboration on Cosmetics Safety hopes to counter hesitations in replacing animal tests.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By Eileen Francis and Lauren Nardella

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.